Evidence map›Paper›PMID 38954151›Full record

ArticleDiscover oncology2024

The value of

Yajing Wang, Jieping Song, Lulu Yang, Wencheng Li, Wei Wang, Aiqing Ji, Liwei Wang, Feng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yajing Wang *Department of Radiology, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China.
Jieping Song *Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China.
Lulu YangDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Wencheng LiDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Wei WangDepartment of Radiology, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China.
Aiqing JiDepartment of Radiology, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China.
Liwei WangDepartment of Radiology, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China. liwei8031@outlook.com.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68Th Changle Road, Nanjing, 210006, China. fengwangcn@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the diagnostic value of

methodsThe PET/CT images and clinical data of 221 patients were retrospectively analyzed. These patients all had clear pathological results. The maximum standard uptake value (SUVmax) of the main lesions was measured at the postprocessing workstation and was tested for correlation with the pathological score. The diagnostic accuracy was calculated using the receiver operating characteristic (ROC) curve, and the best diagnostic threshold was calculated. The correlation between SUVmax and the International Society of Urological Pathology Grade Group (GG) was also analyzed.

resultsThe pathological results of the 221 patients were 48 benign lesions and 173 malignant lesions, including 81 PPC. Low-, intermediate-, and high-risk prostate cancers made up 21.97% (38/173), 54.33% (94/173), and 23.70% (41/173) of the malignant lesions, respectively. SUVmax and GG were positively correlated (r = 0.54, P < 0.01). The best SUVmax thresholds for

conclusion

Indexed as

Positron-emission tomographyProstateProstate-specific membrane antigenTumor

Identifiers

PMID38954151
PMCPMC11219597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.